OND Reorg Getting Warm Welcome From Review Divisions
Executive Summary
Division directors are embracing the reorganization of US FDA's drug review operations.
You may also be interested in...
OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
US FDA Expands 'Cures' Hiring Authority To Fill Variety Of Open Positions
Originally used for leadership positions, the alternative pay scale and a revamped hiring pilot are now shortening the time for FDA to onboard even technical staff, but the Office of New Drugs remains 'very understaffed.'
US FDA 'Uni-Review' Rolls Out: Psychiatric Division Is Among Early Adopters
Shared review memorandum under Office of New Drugs reorg will help eliminate last-minute surprises between disciplines and provide greater consistency between divisions.